Gyre Therapeutics, Inc. (GYRE)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 1124105 · fiscal year ends in Dec
Closing price $6.38 on 29 Oct 2026; 52-week range $5.56 to $8.76.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $119.4M
- Revenue growth
- 16.8%
- Net income, last twelve months
- -$32.1M
- Earnings per share
- -$0.21
- Gross margin
- 94.3%
- Operating margin
- -14.0%
- Net margin
- -26.9%
- Free cash flow
- -$15.7M
- Return on equity
- -29.7%
- Market value
- $676.5M
- Cash
- $43.3M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 106.0M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $116.6M | $11.5M | $5.0M | $0.02 | -$180.0K | 10-K filed 13 Mar 2026 |
| FY2024 | 31 Dec 2024 | $105.8M | $16.2M | $12.1M | $0.05 | -$6.0M | 10-K filed 17 Mar 2025 |
| FY2023 | 31 Dec 2023 | $113.5M | -$67.2M | -$92.9M | -$1.41 | $17.4M | 10-K filed 27 Mar 2024 |
| FY2022 | 31 Dec 2022 | $102.3M | $9.2M | $2.3M | $0.03 | $5.7M | 10-K filed 27 Mar 2024 |
| FY2021 | 31 Dec 2021 | $7.3M | -$87.9M | -$87.9M | -$2.87 | -$84.6M | 10-K filed 31 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $29.1M | -$14.3M | -$0.12 |
| Q1 FY2026 | 31 Mar 2026 | $22.5M | -$18.6M | -$0.10 |
| Q4 FY2025 | 31 Dec 2025 | $37.2M | -$5.2M | -$0.02 |
| Q3 FY2025 | 30 Sep 2025 | $30.6M | $5.9M | $0.03 |
| Q2 FY2025 | 30 Jun 2025 | $26.8M | $1.6M | $0.00 |
| Q1 FY2025 | 31 Mar 2025 | $22.1M | $2.7M | $0.00 |
| Q4 FY2024 | 31 Dec 2024 | $27.9M | -$2.8M | $0.00 |
| Q3 FY2024 | 30 Sep 2024 | $25.5M | $2.9M | $0.01 |
Company events
The newest 8-K filings of 317 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 22 Oct 2026 | 8-K | Leadership change | 5.02, 9.01 |
| 1 Sep 2026 | 8-K | Investor update | 7.01, 9.01 |
| 26 Aug 2026 | 8-K | Investor update | 7.01, 9.01 |
| 7 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 16 Jul 2026 | 8-K | Leadership change, Investor update | 5.02, 7.01, 9.01 |
| 15 Jul 2026 | 8-K/A | Results | 2.02, 9.01 |
| 16 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 2 Jun 2026 | 8-K | Investor update | 7.01, 9.01 |
| 14 May 2026 | 8-K | Investor update | 7.01, 9.01 |
| 12 May 2026 | 8-K | Investor update | 7.01, 9.01 |
| 7 May 2026 | 8-K | Results | 2.02, 9.01 |
| 4 May 2026 | 8-K | Deal completed, Leadership change, Share sale, Shareholder rights change, Bylaws or fiscal year change, Investor update | 2.01, 3.02, 3.03, 5.02, 5.03, 7.01, 9.01 |
Every filing
The newest filings with the SEC of 641 held.
| Filed | Form | Period |
|---|---|---|
| 22 Oct 2026 | 8-K | 16 Oct 2026 |
| 1 Sep 2026 | 8-K | 1 Sep 2026 |
| 27 Aug 2026 | S-8 | – |
| 26 Aug 2026 | 8-K | 26 Aug 2026 |
| 7 Aug 2026 | 10-Q | 30 Jun 2026 |
| 7 Aug 2026 | 8-K | 7 Aug 2026 |
| 3 Aug 2026 | EFFECT | – |
| 16 Jul 2026 | 8-K | 10 Jul 2026 |
| 15 Jul 2026 | 8-K/A | 4 May 2026 |
| 13 Jul 2026 | S-3/A | – |
| 23 Jun 2026 | S-3 | – |
| 16 Jun 2026 | 8-K | 10 Jun 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 18 Jun 2026 | Ye Weiguo, Chief Operating Officer | Sale outside a trading plan | 3,000 | $6.35 | $19.1K | 700,000 | 22 Jun 2026 |
| 10 Jun 2026 | Ye Weiguo, Chief Operating Officer | Sale outside a trading plan | 5,000 | $6.24 | $31.2K | 700,000 | 22 Jun 2026 |
| 9 Jun 2026 | Ye Weiguo, Chief Operating Officer | Sale outside a trading plan | 3,000 | $6.15 | $18.4K | 700,000 | 22 Jun 2026 |
| 11 Jun 2026 | Ye Weiguo, Chief Operating Officer | Sale outside a trading plan | 2,800 | $6.17 | $17.3K | 700,000 | 15 Jun 2026 |
| 10 Jun 2026 | Ye Weiguo, Chief Operating Officer | Sale outside a trading plan | 6,418 | $6.21 | $39.9K | 700,000 | 11 Jun 2026 |
| 9 Jun 2026 | Ye Weiguo, Chief Operating Officer | Sale outside a trading plan | 14,500 | $6.14 | $89.0K | 700,000 | 11 Jun 2026 |
| 5 Jun 2026 | Ye Weiguo, Chief Operating Officer | Sale outside a trading plan | 15,401 | $6.40 | $98.6K | 700,000 | 8 Jun 2026 |
| 4 Jun 2026 | Ye Weiguo, Chief Operating Officer | Sale outside a trading plan | 19,575 | $6.13 | $120.0K | 700,000 | 8 Jun 2026 |
| 26 May 2026 | Ye Weiguo, Chief Operating Officer | Sale outside a trading plan | 4,000 | $6.10 | $24.4K | 700,000 | 27 May 2026 |
| 22 May 2026 | Ye Weiguo, Chief Operating Officer | Sale outside a trading plan | 3,500 | $6.08 | $21.3K | 700,000 | 27 May 2026 |
| 21 May 2026 | Ye Weiguo, Chief Operating Officer | Sale outside a trading plan | 12,820 | $6.15 | $78.8K | 700,000 | 22 May 2026 |
| 20 May 2026 | Ye Weiguo, Chief Operating Officer | Sale outside a trading plan | 9,400 | $6.15 | $57.8K | 700,000 | 22 May 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 11 May 2026 | Ye Weiguo, Officer | 300,000 | $2.1M | 13 May 2026 |
| 13 Nov 2025 | Ye Weiguo, Officer | 548,000 | $4.6M | 15 Nov 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 7 May 2026 | Songjiang Ma | 13D amended | 6.33% | 7.3M |
| 6 May 2026 | Ying Luo | 13D amended | 8.6% | 10.2M |
| 6 May 2026 | GNI USA, Inc. | 13D amended | 69.1% | 86.3M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 1.9M | +0.48% | 16.3 |
| 30 Sep 2026 | 1.9M | +10.88% | 6.92 |
| 15 Sep 2026 | 1.7M | +1.22% | 19.22 |
| 31 Aug 2026 | 1.7M | -2.09% | 34.43 |
| 14 Aug 2026 | 1.7M | -4.27% | 31.05 |
| 31 Jul 2026 | 1.8M | -10.74% | 37.39 |
| 15 Jul 2026 | 2.0M | +11.85% | 24.18 |
| 30 Jun 2026 | 1.8M | +4.97% | 11.78 |
Funds that hold it
From each fund's latest Form 13F.
66 funds held it at 30 Jun 2026: 42 added and 10 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| HSG Holding Ltd | 3,750,299 | $24.7M | +3,750,299 |
| BlackRock, Inc. | 993,943 | $6.6M | +235,313 |
| Octagon Capital Advisors LP | 954,416 | $6.3M | +954,416 |
| Vanguard Capital Management LLC | 876,927 | $5.8M | -107,277 |
| Geode Capital Management, LLC | 532,950 | $3.5M | +101,536 |
| State Street Corp. | 245,402 | $1.6M | +29,076 |
| Charles Schwab Investment Management Inc. | 184,286 | $1.2M | +19,048 |
| Northern Trust Corp. | 169,537 | $1.1M | +35,696 |
| SBI Securities Co., Ltd. | 166,750 | $1.1M | -4,087 |
| Vanguard Fiduciary Trust Co. | 151,073 | $995.6K | +13,391 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B